These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33509675)

  • 21. The immunomodulatory effect of ketamine in depression.
    Szałach ŁP; Lisowska KA; Słupski J; Włodarczyk A; Górska N; Szarmach J; Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wiglusz MS; Wilkowska A; Cubała WJ
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):252-257. PubMed ID: 31488736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frontiers in Therapy of Treatment-Resistant-Depression: A Future Role of Ketamine?
    Kwak S; Tiller D; Tucker P
    J Okla State Med Assoc; 2015 Mar; 108(3):88-9. PubMed ID: 26242015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression.
    De Gioannis A; De Leo D
    Aust N Z J Psychiatry; 2014 Jul; 48(7):686. PubMed ID: 24452289
    [No Abstract]   [Full Text] [Related]  

  • 24. Intravenous ketamine for treatment-resistant major depressive disorder.
    Covvey JR; Crawford AN; Lowe DK
    Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continuation phase intravenous ketamine in adults with treatment-resistant depression.
    Vande Voort JL; Morgan RJ; Kung S; Rasmussen KG; Rico J; Palmer BA; Schak KM; Tye SJ; Ritter MJ; Frye MA; Bobo WV
    J Affect Disord; 2016 Dec; 206():300-304. PubMed ID: 27656788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression.
    Ford N; Ludbrook G; Galletly C
    Aust N Z J Psychiatry; 2015 Dec; 49(12):1227. PubMed ID: 26058787
    [No Abstract]   [Full Text] [Related]  

  • 27. S-(+)-ketamine-induced dissociative symptoms as a traumatic experience in patients with treatment-resistant depression.
    Correia-Melo FS; Silva SS; Araújo-de-Freitas L; Quarantini LC
    Braz J Psychiatry; 2017; 39(2):188-189. PubMed ID: 28591272
    [No Abstract]   [Full Text] [Related]  

  • 28. Can ketamine be a safe option for treatment-resistant bipolar depression?
    Singh B; Vande Voort JL; Frye MA; Kung S
    Expert Opin Drug Saf; 2022 Jun; 21(6):717-720. PubMed ID: 35188015
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of copper and ketamine in major depressive disorder - an update.
    Słupski J; Słupska A; Szałach ŁP; Włodarczyk A; Górska N; Szarmach J; Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wilkowska A; Wiglusz MS; Cubała WJ
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):520-523. PubMed ID: 31488784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Future of Ketamine in the Treatment of Teen Depression.
    Parikh T; Walkup JT
    Am J Psychiatry; 2021 Apr; 178(4):288-289. PubMed ID: 33789452
    [No Abstract]   [Full Text] [Related]  

  • 31. [Ketamine infusion therapy in treatment-resistant depression].
    Christodoulakis ΤΕ
    Psychiatriki; 2021 Dec; 32(Supplement I):64-69. PubMed ID: 34990381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg.
    McIntyre RS
    Am J Psychiatry; 2021 Dec; 178(12):1130-1132. PubMed ID: 34855455
    [No Abstract]   [Full Text] [Related]  

  • 33. Intranasal esketamine for depression: Not so special K.
    Rosenman S
    Australas Psychiatry; 2022 Aug; 30(4):533-534. PubMed ID: 35491953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
    McIntyre RS; Rosenblat JD; Nemeroff CB; Sanacora G; Murrough JW; Berk M; Brietzke E; Dodd S; Gorwood P; Ho R; Iosifescu DV; Lopez Jaramillo C; Kasper S; Kratiuk K; Lee JG; Lee Y; Lui LMW; Mansur RB; Papakostas GI; Subramaniapillai M; Thase M; Vieta E; Young AH; Zarate CA; Stahl S
    Am J Psychiatry; 2021 May; 178(5):383-399. PubMed ID: 33726522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of non-suppression of cortisol levels in a patient with refractory depression receiving ketamine.
    Ostroff R; Kothari JS
    Am J Psychiatry; 2015 Jan; 172(1):95-6. PubMed ID: 25553498
    [No Abstract]   [Full Text] [Related]  

  • 36. A historical review of antidepressant effects of ketamine and its enantiomers.
    Wei Y; Chang L; Hashimoto K
    Pharmacol Biochem Behav; 2020 Mar; 190():172870. PubMed ID: 32035078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
    Bobo WV; Vande Voort JL; Croarkin PE; Leung JG; Tye SJ; Frye MA
    Depress Anxiety; 2016 Aug; 33(8):698-710. PubMed ID: 27062450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short - Term Ketamine Administration in Treatment - Resistant Depression: Focus on Cardiovascular Safety.
    Del Sant L; Sarin LM; de Jesus Mari J
    Psychiatr Danub; 2020; 32(2):219-220. PubMed ID: 32796789
    [No Abstract]   [Full Text] [Related]  

  • 39. Ketamine as an alternative treatment for treatment-resistant depression.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
    [No Abstract]   [Full Text] [Related]  

  • 40. [Off-label ketamine treatment for treatment-resistant depression: win-win?].
    Smith-Apeldoorn SY; Veraart JKE; Schoevers RA
    Tijdschr Psychiatr; 2019; 61(8):516-518. PubMed ID: 31512733
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.